

# 1 Spreading of a lidocaine formulation on microneedle treated skin

2  
3 **Atul Nayak, Diganta B. Das\*, Tzu C. Chao, Victor M. Starov**

4  
5 Department of Chemical Engineering, Loughborough University, Loughborough LE11 3TU,  
6 Leicestershire, UK

7  
8 \*Corresponding author (Email: [D.B.Das@lboro.ac.uk](mailto:D.B.Das@lboro.ac.uk))

## 9 10 **Abstract**

11 The spreadability of a liquid drug formulation on skin is an indication of it either remaining  
12 stationary or distributing (spreading) as a droplet. Factors determining droplet spreadability of  
13 the formulation are spreading area, diameter of the droplet base, viscosity of the liquid, contact  
14 angle, volume of droplet on skin and any others. The creation of microcavities from the  
15 application of microneedle (MN) has the potential to control droplet spreading, and hence, target  
16 specific areas of skin for drug delivery. However, there is little work that demonstrates spreading  
17 of liquid drug formulation on MN treated skin. Below, spreading of a lidocaine hydrogel  
18 formulation and lidocaine solution (reference liquid) on porcine skin is investigated over MN  
19 treated skin. Controlled spreadability was achieved with the lidocaine hydrogel on MN treated  
20 skin as compared with lidocaine solution. It was observed that the droplet spreading parameters  
21 such as spreading radius, droplet height and dynamic contact angle were slightly lower for the  
22 lidocaine hydrogel than the lidocaine solution on skin. Also, the lidocaine hydrogel on MN  
23 treated skin resulted in slower dynamic reduction of droplet height, contact angle and reduced  
24 time taken in attaining static advancing droplets due to the MN microcavities.

25 **Keywords:** Spreadability; Lidocaine; Microneedles; Microcavities; Porcine Skin

## 26 **1.0 Introduction**

27 Percutaneous absorption/permeation of a drug molecule (e.g., lidocaine) through skin depends  
28 on the contact between the formulation and skin properties through which the drug molecules  
29 are absorbed into different skin layers. The possibility of the drop of a liquid drug formulation  
30 either remaining static or distributing (spreading) horizontally on the skin surface relies on its  
31 spreadability. If the droplet is capable of spreading, then the contact line between the  
32 formulation and skin moves over the skin. The rate of movement of the contact line can be  
33 defined as the spreadability of the formulation.

34  
35 Spreadability has significant importance in localised application and efficacy of topical drugs  
36 (Chow et al., 2007). However, the characteristic time scales for spreading of a drug formulation  
37 on skin (~seconds to minutes) is significantly smaller than the characteristic time scales for drug  
38 absorption/permeation into skin (~10s of minutes to hours). Therefore, most studies of  
39 percutaneous or transdermal drug delivery do not characterise spreading behaviour of the drug  
40 formulation over skin. Spreadability is primarily determined by the area/diameter of the

41 formulation droplet on a substrate (e.g., skin below), viscosity of the formulation, contact angle,  
42 the volume of a droplet (permeant amount) (Jelvehgari and Montazam, 2011), and other factors.

43  
44 Over recent years a number of researchers have discussed the possibility of enhanced  
45 permeation of lidocaine (a common anaesthetic) via a 'poke and patch' approach with the help  
46 of solid microneedle (MN) arrays (Banks et al., 2011; Hamzah et al., 2012; Nayak et al.,  
47 2014a,b). This approach involves treating the skin with well-defined MNs to create microcavities  
48 in skin followed by the deposition of a droplet of lidocaine solution on the MN treated area. For  
49 example, Nayak et al. (2014a,b, 2015) demonstrated this approach using a lidocaine  
50 NaCMC:gel 1:2.3 hydrogel formulation and determined the permeation profiles of lidocaine in  
51 porcine skin. While the lidocaine droplets spread over the skin, the lidocaine molecules also  
52 permeate through the treated area (Nayak et al., 2014a,b; Nayak et al., 2015). The duration of  
53 lidocaine hydrogel droplet spreading is in seconds, which is much faster as compared with that  
54 for drug permeation which normally takes about an hour to reach equilibrium lidocaine  
55 concentration in skin.

56  
57 It is known that MNs have been primarily developed to control the mass transfer distance and  
58 time as a drug molecule is absorbed in the skin. However, the creation of microcavities using  
59 MN to accelerate penetration in the skin (Figure 1) allows controlling of spreading of the drug  
60 formulation droplet on skin and, hence, targeting a specific skin area over which the drug  
61 absorption/permeation can take place. On the other hand, a liquid droplet on a normal skin (i.e.,  
62 untreated skin) is likely to spread in a low controlled manner, with low reproducibility and more  
63 rapidly as compared with a MN treated skin. At the moment, there is little or no study that  
64 specifically analyses in detail such spreading dynamics of drug formulation on MN pierced skin  
65 and the role that the MN cavities play in determining the formulation spreading behaviour. This  
66 work aims to address this gap.

67  
68 Below, lidocaine was loaded in a hydrogel biopolymer with a gel to NaCMC mass ratio of 2.3 as  
69 discussed earlier in Nayak et al. (2014a,b) and Nayak et al. (2015). This mass ratio represents  
70 optimum drug and vehicle physico-chemical properties for a formulation (Nayak et al., 2014a,b).  
71 For the developed approach, controlling the spreadability of lidocaine hydrogel on skin is  
72 important to acquire liquid distribution of a liquid over the skin surface. A slower droplet  
73 spreading on skin coupled with a faster time in attaining static advancing contact angle is a  
74 favourable outcome in ensuring localised permeation of lidocaine at the treatment site.

75  
76 Lidocaine NaCMC:gel 1:2.3 hydrogel is a non-Newtonian liquid at standard room temperatures  
77 and pressure (Nayak et al., 2014a). The Ostwald de Waele power law can be used to describe  
78 the pseudoplastic behaviour of for such a fluid as follows:

79  
80 
$$\eta = k(\dot{\gamma})^{n-1} \quad . \quad (1)$$

81  
82 Where  $\eta$  is the apparent viscosity,  $\dot{\gamma}$  is the shear rate,  $k$  is the consistency constant of the  
83 substance and  $n$  is the power-law or flow index. A log-log plot of viscosity ( $\eta$ ) on shear rate ( $\dot{\gamma}$ )

84 for lidocaine NaCMC:gel 1:2.3 taken from Nayak et al. (2014a) provides an index value  $n =$   
85 0.392. As the index value is less than 1, the fluid is identified as pseudoplastic (Fang and Hanna,  
86 1999). Its physical property can be exploited in quantifying and controlling the spreading of a  
87 lidocaine hydrogel droplet on an untreated flat skin surface without the need for manual rubbing  
88 across the whole area. For example, the pseudoplastic properties of the hydrogel is likely to  
89 provide a better control in droplet spreading as discussed earlier by Nayak et al. (2014b).

90  
91 Below a comparison of spreadability between lidocaine NaCMC:gel 1:2.3 hydrogel (higher  
92 viscosity) and lidocaine solution (lower viscosity) is conducted in order to understand the  
93 spreading behaviour. The loading dosage of lidocaine in both the hydrogel and solution form  
94 containing water was 2.4% w/w. The objective of the study is to examine the spreadability of  
95 lidocaine NaCMC:gel 1:2.3 hydrogel droplets on MN treated and untreated skin in relation to the  
96 viscosity of the formulation. Surface layers of skin treated with MN contain microcavities, which  
97 allow controlling the spreading of the lidocaine hydrogel and achieving static advancing contact  
98 angles and decreased spreading radius faster as compared with untreated skin. Three different  
99 MN types are applied to the skin samples in order to create controlled cavity depths past ~  
100 15 $\mu$ m thick stratum corneum (SC) layer of skin. Evaporation of the droplet is defined to be  
101 negligible due to the high boiling point of residual paraffin content in the lidocaine hydrogel, and  
102 relatively short duration of the spreading experiments. Our study specifically focuses on a drug  
103 formulation spreading on MN treated skin, which is the first attempt to investigate this process to  
104 the best of our knowledge.

105

## 106 **2.0 Materials and Methods**

107 A lidocaine NaCMC:gel 1:2.3 hydrogel formulated by Nayak et al. (2014a) was adopted for  
108 characterising spreadability on porcine skin. The method of preparation of the hydrogel can be  
109 found in Nayak et al. (2014a,b) and Nayak et al. (2015). As stated earlier, the gel to NaCMC  
110 mass ratio of 2.3 was chosen for this study because of a faster permeation of lidocaine into the  
111 skin. The lidocaine NaCMC:gel 1:2.3 hydrogels were formulated using the vacuum oven method  
112 during final stage evaporation of excess paraffin dissolved in n-hexane as described in Nayak et  
113 al. (2014a,b). To prepare lidocaine solution, lidocaine HCl (> 98% assay) was added to  
114 deionised water and heated gently to ensure a dissolved solution at 2.4% w/w. However, no  
115 lidocaine permeability experiments were conducted below. This work is focussed on  
116 determining the spreading radii, droplet heights, dynamic contact angles and characteristic  
117 spreading times of lidocaine hydrogel and solution (i.e., lidocaine dissolved in deionised water)  
118 on both porcine skin and an artificial skin membrane, namely, Strat-M.

119

## 120 **2.1 Reagents and Materials**

121 Lidocaine HCl (Sigma Aldrich UK, Dorset, UK), lidocaine NaCMC:gel 1:2.3 hydrogels,  
122 autopipette 0-10  $\mu$ l (Thermofisher Ltd, Warrington, UK), Camera i-speed LT high speed video  
123 (Olympus, Essex, UK), MNs (AdminPatch, California, U.S.A), porcine skin (local butcher, UK),  
124 piston enabled pressure/force device (SMC pneumatics Ltd, Buckinghamshire, UK), synthetic  
125 transdermal membrane (Strat-M™, Merck Millipore, Hertfordshire, UK), temperature and

126 humidity probe (Standard, Maplin Electronics, Leicestershire, UK) were used in experiments  
127 below.

128

## 129 **2.2 Preparation of skin for spreading experiments**

130 The procedures for skin preparation were similar to the ones used for Franz diffusion cell (FDC)  
131 experiments for determining drug permeation in skin, e.g., please see methods stated by Nayak  
132 et al. (2014a,b). Briefly, these procedures involved the following steps: (i) either fresh porcine  
133 skin pieces originating from the porcine ears were washed in deionised water and dried using a  
134 tissue, or frozen porcine skin pieces originating from the porcine ears were thawed at room  
135 temperature, washed in deionised water and dried using a tissue; (ii) the cartilage,  
136 subcutaneous fat, blood vessels and connective tissue were removed from the underlying  
137 dermis sections of all skin samples; (iii) the skin samples were dissected further into 10 mm x 10  
138 mm square pieces; (iv) the skin was placed on microscope slides with SC layer facing upwards  
139 for observation of the spreading dynamics.

140

## 141 **2.3 MN treatment of skin**

142 Stainless steel MNs of two lengths (1100 $\mu$ m and 600 $\mu$ m) were placed in the centre of a  
143 prepared porcine skin sample. A perpendicular piston barrel device (SMC pneumatics Ltd, serial:  
144 CD85N16-50-B) was used for transmission of controlled pressure induced force onto the  
145 chosen MN as described by Cheung et al. (2014). Using the system, constant pressures of 0.5  
146 bar, 1.0 bar and 2.0 bar equating to impact forces of 3.9 N, 7.9 N and 15.7 N were held for five  
147 minutes on the base of the MN (Nayak et al., 2015; Cheung et al., 2014). The forces (3.9 N, 7.9  
148 N and 15.7 N) used to treat the skin with the MNs (Nayak et al., 2015). The MN patch was  
149 removed from the porcine skin prior to droplet spreading experiments.

150

## 151 **2.4 Spreading of lidocaine NaCMC:gel 1:2.3 over skin surface**

152 The experimental procedures for studying the spreading of lidocaine hydrogel droplet on  
153 porcine skin were adapted from Chao et al. (2014). A lidocaine hydrogel droplet (volume of 3.0  
154  $\pm$  0.5  $\mu$ l) was deposited using a pipet onto a piece of skin resting on a microscope slide as  
155 carefully as possible to prevent splashing or fast inertial spreading. The i-speed LT high speed  
156 camera (Olympus, UK) recorded 1.85 frames per second until a stationary droplet profile or full  
157 disappearance was reached. The procedure was repeated twice for the control lidocaine  
158 solution. The real time capture of stages of the droplet spreading by camera configurations (i-  
159 speed, LT high speed) focused on the droplet is presented in Figure 2. This arrangement is  
160 based on liquid spreading and imbibition experiments for Newtonian liquids (Chao et al., 2014)

161

## 162 **2.5 Spreading of lidocaine NaCMC:gel 1:2.3 hydrogels on the surface of artificial skin** 163 **Strat-M membrane**

164 Besides porcine skin, synthetic membrane which is sometimes used as a substitute for skin in  
165 transdermal *in vitro* studies were used as a substrate. These are composed of polyethersulfone  
166 and polyolefin and are known by the trade name Strat-M (Merck Millipore Ltd, Hertfordshire,  
167 UK). Strat-M membranes were chosen as control matrices for spreadability studies because of a  
168 relatively uniform flat surface as compared with the less uniform and rough surfaces of natural  
169 skin samples.

170  
171 The characterisation of droplet spreading parameters, especially contact angles, was adopted  
172 from Chao et al. (2014). A square section of membrane substrate (15 mm x 15 mm) from a  
173 larger section was cut and taped to an edge of the glass side. This allows closer distance and  
174 improved resolution between the droplet and the camera lens. A hydrogel droplet of volume  $3.0$   
175  $\pm 0.5 \mu\text{l}$  was immediately deposited on the membrane in the same way as in the case a natural  
176 skin. The recording procedure was identical to that described in the previous section. The  
177 droplet images of all formulations used were processed using Vision Builder software (National  
178 Instrument, UK) to determine droplet spreading parameters: contact angle, droplet height and  
179 spreading radius.

180  
181 **2.6 The measurement of relative humidity and temperature**  
182 The percentage relative humidity (% RH) and temperature of the droplet environment were  
183 recorded using an electronic probe (Standard, Maplin Electronics, Leicestershire, UK). The data  
184 were acquired in triplicate.

185  
186 **3.0 Results and Discussion**  
187  
188 Comparative trends for lidocaine droplet spreading on porcine skin samples and Strat-M  
189 membrane were deduced starting with lidocaine solution as a control sample. The results are  
190 discussed below.

191  
192 **3.1 Spreadability of lidocaine 2.4 % w/w solution (lidocaine dissolved in DI water)**  
193  
194 The spreading of lidocaine 2.4% w/w solution droplets on normal skin (i.e., untreated porcine  
195 skin) were significantly more rapid and showed an almost linear dependence of spreading  
196 radius on time as compared with those for MN treated skin (Figure 3a). Likewise, the droplet  
197 heights of lidocaine solution droplets showed faster reduction and the droplet heights at static  
198 profiles was achieved after approximately 130 seconds (Figure 4a). The dynamic contact angle  
199 for the same case showed a faster reduction reaching the static advancing contact angle  
200 approximately of  $11^\circ$  after 130 seconds (Figure 5a). A sharp reduction in the contact angle was  
201 observed within the first 40 seconds for the lidocaine solution on the untreated skin. This  
202 suggests a slightly steeper reduction profile as compared with that for the lidocaine solution on  
203 3.9 N MN treated skin for MNs of 600 and 1100 $\mu\text{m}$  lengths, respectively (Figure 5d). The  
204 microcavity depths for both 600 $\mu\text{m}$  and 1100 $\mu\text{m}$  long MNs are expected to be shallow for the  
205 force applied on the MNs (Nayak, et al., 2015) and, therefore, significantly less reduction in the  
206 contact angles was observed when compared with those for non-MN treated skin (Figure 5c).

207  
208 Droplets of the lidocaine solution have an initial contact angle of  $57.1^\circ$  at the moment of  
209 deposition ( $t \approx 0$ ) on the non-MN treated skin. The viscosity of lidocaine solution is very similar to  
210 DI water and both are Newtonian fluids. However, the initial contact angle was near  $90^\circ$  for DI  
211 water on non-MN treated skin as reported earlier by Elkhyat et al. (2004), which is significantly  
212 higher than observed for the lidocaine solution. The high contact angle of DI water was caused

213 by the low sebum content on skin and there is a big variation in the initial contact angle  
214 depending on skin location (Elkhyat et al., 2004). Sebum is a natural mixture of lipids. Lidocaine  
215 solution on non-MN treated skin is devoid of artificial cavities and excess liquid cannot retain  
216 inside cavities and slow down droplet spreading.

217  
218 The 1100  $\mu\text{m}$  long MN induced microcavity depths for 3.9 N, 7.9 N and 15.7 N forces are  
219 reported to be 19.5  $\mu\text{m}$ , 23.1  $\mu\text{m}$  and 26.7  $\mu\text{m}$ , respectively (Nayak et al., 2015). The mean  
220 microcavity depths using 600  $\mu\text{m}$  long MN for the same forces are small but they are not easily  
221 detectable for transverse visualisation of skin microcavities as the forces applied are relatively  
222 small (implying smaller microcavity length). However, AdminPatch<sup>TM</sup> microneedles at 600 $\mu\text{m}$   
223 length are shown to increase drug permeation. For example, drug permeability studies by Kaur  
224 et al. (2014) demonstrated a 14.3 fold increase in permeation flux as compared with passive  
225 diffusion for the transdermal delivery of an anti-hypertensive agent, thus implying that  
226 microcavities were formed in skin. These depths cross the typical SC layer depth of 15  $\mu\text{m}$   
227 (Nayak et al., 2015).

228  
229 The dynamic contact angles of lidocaine solution on 7.9 N force treated MN skin outlines slow  
230 decreases in contact angles, which is especially more significant for the 1100  $\mu\text{m}$  long MNs  
231 (Figure 5a). The spreading radius and droplet height of lidocaine solution are significantly less  
232 for 7.9 N force treated skin (Figures 3a and 4a). This is because of deeper MN cavities  
233 capturing excess liquid during droplet spreading of lidocaine solution. Nevertheless, it was not  
234 possible to determine using conventional cryotome techniques if a large quantity of MN in a  
235 patch created a uniform depth microcavity for both specific MN lengths. MNs were impacted on  
236 skin for 5 minutes maximum using one specific force, so an assumption that most MNs have  
237 successfully pierced skin at significant microcavity depths will be made here.

238

### 239 **3.2 Spreadability of lidocaine NaCMC:gel 1:2.3 hydrogel**

240 The spreading of lidocaine NaCMC:gel 1:2.3 hydrogel show similar trends for 600 $\mu\text{m}$  long MN  
241 treated skin, particularly closer for 3.8 N and 7.8 N forces (Figure 3c). The fluid properties of the  
242 formulation which affect the spreading behaviour have been discussed earlier (Nayak et al.,  
243 2014a, b).

244  
245 The 15.7 N force on a 600 $\mu\text{m}$  MN patch treated skin showed increasing spreading radius than  
246 3.9 N as compared with the lowest force of the same MN length (Figure 3c). This is because the  
247 MN cavity depths are likely not to be deep enough. The reason is because of an observable  
248 reduction in spreading radius caused by deeper micro-cavities from higher MN forces. Lidocaine  
249 hydrogel droplets for the insertion forces of 3.9 N, 7.9 N and 15.7 N for 1100  $\mu\text{m}$  long MNs  
250 provide less rapidly increasing spreading radius, less rapidly decreasing droplet heights and  
251 less rapidly decreasing dynamic contact angles (Figures 3c, 4c and 5c) before static profiles  
252 were reached. Nevertheless, there were minor contradictions in reporting lower spreading radii  
253 when droplet heights were not decreasing rapidly because of the mild pseudoplastic properties  
254 of the lidocaine hydrogel (Nayak et al., 2014a). For example, lidocaine hydrogel from 3.9 N,  
255 600 $\mu\text{m}$  treated skin should hypothetically outline faster spreading than 7.9 N, 1100 $\mu\text{m}$  on skin  
256 because the latter usually possess deep microcavities (Figure 3c). Skin microcavities created by

257 MNs do not produce exact replicates of microcavity lengths as shown in transverse section  
258 micrographs due to variability in the viscoelastic property of skin (Nayak et al., 2015). Further,  
259 lidocaine hydrogel droplets were sometimes difficult to dispense with accurate volumes within  $\pm$   
260  $0.05 \mu\text{l}$  because of the viscous nature of the formulation.

261  
262 The results show that the lidocaine solution spreading radii for 3.9 N and 7.9 N forces of 1100  
263  $\mu\text{m}$  long (longer MNs) MN is distinctly different as compared to the lidocaine hydrogel spreading  
264 radii (Figures 3a and 3c). However, no significant difference in droplet spreading radii was  
265 observed when comparing 3.9 and 7.9 N force of 600  $\mu\text{m}$  long MN (shorter MNs) for lidocaine  
266 solution (Figure 3a). In further scrutinising spreading patterns the lidocaine solution showed  
267 rapid spreading, faster decrease in droplet height and rapid decrease in dynamic contact angle  
268 as compared with lidocaine hydrogel when the same forces, namely, 3.9 N force was applied on  
269 the skin (Figure 3d).

270  
271 The artificial membrane (Strat-M), which is normally implemented in drug based *in vitro* passive  
272 diffusion studies, was a control for skin because of a relatively smooth surface (Uchida et al.,  
273 2015). The spreading radii of lidocaine solution and hydrogel droplets could not be measured  
274 reliably with a good repeatability because of the horizontal placement of camera and liquid  
275 percolation through the pores in the membrane. However, there is a slight decrease in droplet  
276 height and dynamic contact angle for lidocaine solution droplets (Figures 4b and 5b). This slight  
277 decrease can be attributed to the percolation of lidocaine solution into Strat-M pores despite no  
278 significant change in droplet spreading radius.

279  
280 Lidocaine hydrogel droplets showed significant change in spreading radius, droplet height and  
281 dynamic contact angle (Figures 4b, 5b) on Strat-M. The droplet spreading was likely to be  
282 caused by the lower surface tension of lidocaine hydrogel on the hydrophobic surface of Strat-M.  
283 Lidocaine hydrogel contains residual paraffin of low surface tension properties as compared  
284 with water.

285  
286 Lidocaine hydrogels and lidocaine solution droplets snapshots outline spreading in terms of  
287 observed changes in droplet shape at three distinct timings (Figures 6 and 7). Lidocaine  
288 solution droplets have dome shape at the initial time of placement as compared with slightly  
289 flattened dome shaped droplets for lidocaine hydrogel (Figures 6 and 7). After a duration of 10  
290 seconds, the lidocaine hydrogels spread more than the lidocaine solution, especially on skin  
291 treated with 600  $\mu\text{m}$  long MNs (Figures 6 and 7). In most cases, lidocaine solution shows  
292 distinct droplet with respect to 7.9 N force with 1100 $\mu\text{m}$  long MN treated skin and Strat-M  
293 membrane after 180 seconds (Figure 6). The remaining MN treated skin variables appear not to  
294 retain more lidocaine solution droplets in the microcavities (Figure 6). After the duration of 180  
295 seconds, the droplet outline is distinctly notable for lidocaine hydrogel after 1100 $\mu\text{m}$  MN  
296 treatment on skin (Figure 7).

297  
298 The relative humidity and temperature of the surrounding vicinity for droplet spreadability was  
299  $48.6 \pm 4.31\%$  at  $20.1 \pm 2.40^\circ\text{C}$ , respectively. The standard deviation for relative humidity is  
300 observed because the surroundings are not an isolated system preventing the transfer of heat.

301 Normal environmental changes in relative humidity were expected because the duration of  
302 experiments were conducted upto 3 minutes and relative humidity can fluctuate in a matter of  
303 seconds. The reading of relative humidity of 48.6% is near average at a low room temperature.  
304 The likelihood of evaporation is low for these surrounding conditions and the short duration of  
305 the experiments.

306  
307 **3.3 Dimensionless spreading parameters of lidocaine hydrogel and solution**  
308 The spreading dynamics of lidocaine NaCMC:gel 1:2.3 hydrogel and solution are represented in  
309 this section in terms of dimensionless parameters, namely, dimensionless spreading radius ( $\frac{L_t}{L_m}$ ),  
310 dimensionless contact angle ( $\frac{\theta_t}{\theta_m}$ ), dimensionless droplet height ( $\frac{h_t}{h_m}$ ) and dimensionless  
311 spreading time ( $\frac{t}{t^*}$ ) and dimensionless droplet volume ( $\frac{V_t}{V_{max}}$ ). For the above five dimensionless  
312 parameters, the numerators, namely,  $L_t$ ,  $\theta_t$ ,  $h_t$ ,  $V_t$  and  $t$ , are the droplet spreading radius, contact  
313 angle, height, volume and measured time periodically at different time intervals. On the other  
314 hand, the denominators of the fractions are the droplet base showing the maximum spreading  
315 radius, maximum contact angle, maximum droplet height, maximum droplet volume and static  
316 advancing droplet time. The dimensionless numbers, namely,  $\frac{L_t}{L_m}$ ,  $\frac{\theta_t}{\theta_m}$ ,  $\frac{h_t}{h_m}$  and  $\frac{V_t}{V_{max}}$  are plotted  
317 as function of  $\frac{t}{t^*}$  for various circumstances (Figure 8). Analyses of these parameters provide  
318 understanding of the time evolution of these parameters and give some generality to the results  
319 (e.g., see Chao et al., 2014). Figure 8 shows that the time evolutions of these dimensionless  
320 parameters are different implying that the spreading behaviour is different in different cases.  
321 These are discussed below.

322  
323 The lidocaine hydrogel spreading on 3.9 N and 7.9 N force treated skin with 1100 $\mu$ m and 600  
324  $\mu$ m long MN showed short durations in increasing dimensionless spreading profiles, thus  
325 attaining closeness to a plateau of dimensionless value of 1.0 at a shorter time interval (Figure  
326 8a). The lidocaine solution on non-MN treated skin could not be reported as dimensionless  
327 spreading because a linear profile was observed and  $L_m$  could not be deduced because of no  
328 plateau (Figure 3a).

329  
330 The spreading of lidocaine hydrogels on 7.9 N and 15.7 N force treated skin with 1100  $\mu$ m long  
331 MN showed a long durations in increasing spreading radius; thus, attaining closeness to  
332 dimensionless value 1.0 above the fractional time of 0.90 (Figure 8a). A short duration in  
333 increasing dimensionless spreading means a less dynamic spreading across the skin. As  
334 mentioned earlier in this paper, the lidocaine hydrogel fill the skin microcavities and the  
335 spreading of the hydrogel slow down.

336  
337 All lidocaine hydrogels droplets on MN treated skin outlined slower reduction of dimensionless  
338 droplet height as the liquid fills the microcavities on MN treated skin (Figure 8b). Comparatively,  
339 the lidocaine solutions showed faster dynamic height reduction from maximum spreading height  
340 ( $t = 0$ ) because of high initial droplet height fractions and faster spreading (Figure 8b).

341



342 Slower dynamic reduction of contact angle was observed for all lidocaine hydrogel droplets on  
343 MN treated skin (Figure 8c). The lidocaine hydrogel on 3.9 N of 1100  $\mu\text{m}$  length, 7.9 N and 15.7  
344 N of 600  $\mu\text{m}$  treated skin showed slightly slower reductions in fractional contact angles (Figure  
345 8c). Nevertheless, lidocaine hydrogel on 7.9 N and 15.7 N treated skin samples with 1100  $\mu\text{m}$   
346 long MN outlined slightly faster reductions in the dimensionless contact angle (Figure 8c). Static  
347 advancing droplets were found to arrive at shorter fractional timings for lidocaine hydrogels  
348 because of the viscous property of the hydrogel and presence of numerous MN microcavities as  
349 liquid percolates into the microcavity spaces.

350  
351 The lidocaine solution droplets show significantly more dynamic volume decreases as  
352 compared with lidocaine hydrogel droplets (Figure 9 a,b), which is due to the fact that the  
353 lidocaine solution percolates into the MN holes faster than the lidocaine hydrogel droplets. The  
354 lidocaine hydrogels outline low droplet volume reductions in microneedle treated skin and fast  
355 appearance of static droplet volumes (Figure 9b). There was a faster reduction in droplet  
356 volume for Strat-M and 15.7 N, 1100  $\mu\text{m}$  treated skin (Figure 9b). The roughness of skin and  
357 the pseudoplastic properties of the hydrogel are two factors in explaining the likelihood for the  
358 observed static advancing droplet profiles. Non-microneedle treated skin and Strat-M  
359 membrane surfaces appear smooth, so there appears to be faster droplet volume decreases in  
360 those two substrate control parameters.

361

#### 362 **4.0 Conclusion**

363 The spreading of a liquid drug formulation, namely, lidocaine NaCMC:gel 1:2.3 hydrogel, on MN  
364 treated skin is studied. The results of the study show improved control of the formulation  
365 spreadability as compared to those for lidocaine solution (lidocaine dissolved in deionised water)  
366 alone. Lidocaine NaCMC:gel 1:2.3 hydrogel show a slightly lower spreading radius, slight  
367 decrease in droplet height and smaller, controlled decrease in dynamic contact angle as  
368 compared with lidocaine solution. The slower dynamic reduction of droplet height and contact  
369 angle and convergence to static advancing droplet at short initial timings for lidocaine  
370 NaCMC:gel 1:2.3 hydrogel are indication of the seepage of the liquid inside MN microcavities in  
371 skin.

372

#### 373 **5.0 References**

374 Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL (2011) Diclofenac enables  
375 prolonged delivery of naltrexone through microneedle-treated skin 28: 1211-1219

376

377 Butt HJ, Golovko DS, Bonaccorso E (2007) On the derivation of Young's equation for sessile  
378 Drops: nonequilibrium effects due to evaporation. J Phys Chem B 111: 5277-5283.

379

380 Chao TC, Trybala A, Starov V, Das DB (2014) Influence of haematocrit level on the kinetics of  
381 blood spreading on thin porous medium during dried blood spot sampling. Colloids and  
382 Surfaces A: Physicochemical and Engineering Aspects 451: 38-47.

383

384 Cheung K, Han T, Das DB (2014) Effect of force of microneedle insertion on the permeability of  
385 insulin in skin. Journal of Diabetes Science and Technology 8: 444-452.

386  
387 Chow KT, Chan LW, Heng PWS (2008) Characterization of spreadability of nonaqueous  
388 ethylcellulose gel matrices using dynamic contact angle. *Journal of Pharmaceutical Sciences* 97:  
389 3467-3481.  
390  
391 Courbin L, Bird JC, Reyssat M, Stone HA (2009) Dynamics of wetting: from inertial spreading to  
392 viscous imbibition. *Journal of physics: Condensed matter* 21: 1-13.  
393  
394 Elkhyat A, Courderot-Masuyer C, Mac-Mary S, Courau S, Gharbi T, Humbert P (2004)  
395 Assessment of spray application of Saint GERVAIS® water effects on skin wettability by contact  
396 angle measurement comparison with bidistilled water. *Skin Research and Technology* 10: 283-  
397 286.  
398  
399 Fang Q, Hanna MA (1999) Rheological properties of amorphous and semicrystalline polylactic  
400 acid polymers. *Industrial Crops and Products* 10: 47-53.  
401  
402 Hamzah AA, Aziz NA, Majlis BY, Yunas J, Dee CF, Bais B (2012) Optimization of HNA etching  
403 parameters to produce high aspect ratio solid silicon microneedles. *Journal of Micromechanics*  
404 *and Microengineering* 22: 1-10.  
405  
406 Jelvehgari M, Montazam H (2011) Evaluation of mechanical and rheological properties of  
407 metronidazole gel as local delivery system. *Archives of Pharmacal Research* 34: 931-940.  
408  
409 Kaur M, Ita KB, Popova IE, Parikh SJ, Bair DA (2014) Microneedle-assisted delivery of  
410 verapamil hydrochloride and amlodipine besylate. *European Journal of Pharmaceutics and*  
411 *Biopharmaceutics* 86: 284-291.  
412  
413 Nayak A, Das DB, Vladisavljević GT (2014a) Microneedle-assisted permeation of lidocaine  
414 carboxymethylcellulose with gelatine co-polymer hydrogel. *Pharmaceutical Research* 31:1170–  
415 1184  
416  
417 Nayak A, Babla H, Tao H, Das DB (2014b) Lidocaine carboxymethylcellulose with gelatine co-  
418 polymer hydrogel delivery by combined microneedle and ultrasound. *Drug Delivery*. (Article in  
419 press) DOI: 10.3109/10717544.2014.935985  
420  
421 Nayak A, Short L, Das DB (2015) Lidocaine permeation from a lidocaine NaCMC/gel microgel  
422 formulation in microneedle pierced skin: vertical (depth averaged) and horizontal permeation  
423 profiles. *Drug Delivery and Translational Research*. (Article in press). DOI: 10.1007/s13346-  
424 015-0229-z  
425  
426 Shields PA, Ling TF, Tjatha V, Shah DO, Farraha SR (1986) Comparison of positively charged  
427 membrane filters and their use in concentrating bacteriophages in water. *Water Research* 20:  
428 145-151.  
429

430 Strat-M. Compound Correlation Tool. Lidocaine (Analgesic) [http://fa24f31db0da67276cd1-](http://fa24f31db0da67276cd1-be593b508d6f5ef1fdddadaa02b1fbea.r66.cf1.rackcdn.com/stratm2.html)  
431 [be593b508d6f5ef1fdddadaa02b1fbea.r66.cf1.rackcdn.com/stratm2.html](http://fa24f31db0da67276cd1-be593b508d6f5ef1fdddadaa02b1fbea.r66.cf1.rackcdn.com/stratm2.html) (Accessed:  
432 08/04/2015).  
433  
434 Tarleton ES, Wakeman RJ (1994) Understanding flux decline in crossflow microfiltration: Part 3.  
435 Effects of membrane morphology. Trans IChemE 72 (A): 521-529.  
436  
437 Uchida T, Kadhum WR, Kanai S, Todo H, Oshizaka T, Sugibayashi K (2015) Prediction of skin  
438 permeation by chemical compounds using the artificial membrane, Strat-M™. European Journal  
439 of Pharmaceutical Sciences 67: 113-118  
440  
441 Ukiwe C, Kwok DY (2005) On the maximum spreading diameter of impacting droplets on well  
442 prepared solid surfaces. Langmuir 21: 666-973.  
443  
444 Wakeman RJ, Tarleton ES (1992) Membrane characterisation: The need for a standard.  
445 Process Industry Journal: 16-19

## List of Figures




Figure 1. A liquid droplet on microneedle treated matrix and percolation of liquid into microcavities. The arrows illustrate droplet spreading radius ( $L$ ), droplet height ( $h$ ) and contact angle ( $\theta$ ).




Figure 2. A schematic diagram of experimental setup for the capture of droplet spreading







Figure 3. Time evolutions of droplet spreading radius for **a)** lidocaine solution on microneedle and non-microneedle treated skin **b)** lidocaine microgels on microneedle treated skin **c)** lidocaine solution and lidocaine microgels on microneedle treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.









Figure 4. Time evolutions of droplet height for **a)** lidocaine solution on microneedle and non-microneedle treated skin **b)** lidocaine solution and lidocaine microgels on Strat-M membrane **c)** lidocaine microgels on microneedle and non-microneedle treated skin **d)** lidocaine solution and lidocaine microgels on microneedle treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.








Figure 5. Time evolutions of dynamic contact angle for **a)** lidocaine solution on microneedle and non-microneedle treated skin **b)** lidocaine solution and lidocaine microgels on Strat-M membrane **c)** lidocaine microgels on microneedle and non-microneedle treated skin **d)** lidocaine solution and lidocaine microgels on microneedle treated skin. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.




Figure 6. Captured images of lidocaine solution droplets (C) on a substrate (skin or membrane) at three different time points. The figure shows the droplet morphology at the substrate for different forces of MN insertion and MN lengths which were used to treat the skin.




Figure 7. Captured images of lidocaine NaCMC:gel 1:2.3 hydrogel droplets (S) on a substrate (skin or membrane) at three different time points. The figure shows the droplet morphology at the substrate for different forces of MN insertion and MN lengths which were used to treat the skin.




Figure 8. The lidocaine droplet plots outlining dynamic variation in **a**) spreading of hydrogel (S) or solution (C) on microneedle and non-microneedle treated skin **b**) droplet height of hydrogel (S) or solution (C) on microneedle and non-microneedle treated skin **c**) contact angle of hydrogel (S) or solution (C) on microneedle and non-microneedle treated skin.




Figure 9 The non-dimensional droplet volume on top of skin sample **a**) for lidocaine solution **b**) lidocaine NaCMC:gel 1:2.3. The abbreviation C is control lidocaine solution and S is sample lidocaine hydrogel.